Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865348 | 0.98 | HRH3 (0.58) | HRH3KCNH2IRAK4CTSSCTSK | |
| SCHEMBL3861953 | 0.96 | HRH3 (0.57) | HRH3KCNH2IRAK4CTSSCTSK | |
| Hydrochloric Acid SCHEMBL3861516 | 0.96 | HRH3 (0.57) | HRH3KCNH2IRAK4CTSSCTSK | |
| Hydrochloric Acid SCHEMBL3879990 | 0.95 | HRH3 (0.56) | HRH3KCNH2IRAK4CTSSCTSK | |
| SCHEMBL3857428 | 0.84 | IRAK4 (0.54) | HRH3IRAK4 | |
| SCHEMBL3767914 | 0.84 | HRH3 (0.51) | HRH3CTSSCTSKMEN1 | |
| SCHEMBL3772223 | 0.82 | HRH3 (0.52) | HRH3KCNH2IRAK4CTSSCTSK | |
| SCHEMBL3862814 | 0.82 | CHRNB2 (0.53) | CTSSCTSKMEN1ALDH1A1MAPT | |
| SCHEMBL13683829 | 0.82 | HRH3 (0.47) | HRH3CTSSCTSK | |
| SCHEMBL3858253 | 0.82 | HRH3 (0.46) | HRH3IRAK4MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592347-B2 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | claimed |
| EP-1615909-B1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | claimed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | claimed |
| CN-1809553-A | Piperazine derivatives and their use in the treatment of neurological and psychiatric disorders | GLAXO GROUP LTD (GB) | 2006-07-26 | — | — | CN | claimed |
| EP-1615909-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2006-01-18 | — | — | EP | claimed |
| WO-2004101546-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | claimed |
| US-7592347-B2 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
| CN-1809553-A | Piperazine derivatives and their use in the treatment of neurological and psychiatric disorders | GLAXO GROUP LTD (GB) | 2006-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | HRH3 1322/4885KCNH2 529/4885IRAK4 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.